DBV Technologies S.A. (DBVT)
NASDAQ: DBVT · Real-Time Price · USD
21.71
+0.45 (2.12%)
Feb 9, 2026, 9:37 AM EST - Market open
DBV Technologies Employees
DBV Technologies had 117 employees as of September 30, 2025. The number of employees increased by 9 or 8.33% compared to the same quarter last year.
Employees
117
Change
9
Growth
8.33%
Revenue / Employee
$47,026
Profits / Employee
-$1,069,513
Market Cap
1.27B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Sep 30, 2025 | 117 | 9 | 8.33% | 117 | 0 |
| Jun 30, 2025 | 109 | 3 | 2.83% | 109 | 0 |
| Mar 31, 2025 | 106 | 1 | 0.95% | 106 | 0 |
| Dec 31, 2024 | 110 | 5 | 4.76% | 109 | 1 |
| Sep 30, 2024 | 108 | 11 | 11.34% | 108 | 0 |
| Jun 30, 2024 | 106 | 18 | 20.45% | 106 | 0 |
| Mar 31, 2024 | 105 | 17 | 19.32% | 105 | 0 |
| Dec 31, 2023 | 105 | 19 | 22.09% | 104 | 1 |
| Sep 30, 2023 | 97 | 12 | 14.12% | 97 | 0 |
| Jun 30, 2023 | 88 | 1 | 1.15% | 88 | 0 |
| Mar 31, 2023 | 88 | 0 | - | 88 | 0 |
| Dec 31, 2022 | 86 | -6 | -6.52% | 85 | 1 |
| Sep 30, 2022 | 85 | -7 | -7.61% | 85 | 0 |
| Jun 30, 2022 | 87 | -10 | -10.31% | 87 | 0 |
| Mar 31, 2022 | 88 | -16 | -15.38% | 88 | 0 |
| Dec 31, 2021 | 92 | -50 | -35.21% | 92 | 0 |
| Sep 30, 2021 | 92 | -219 | -70.42% | 92 | 0 |
| Jun 30, 2021 | 97 | -214 | -68.81% | 97 | 0 |
| Mar 31, 2021 | 104 | -207 | -66.56% | 104 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Fortrea Holdings | 14,500 |
| Novavax | 952 |
| Immatics | 645 |
| Day One Biopharmaceuticals | 184 |
| Inhibrx Biosciences | 161 |
| Capricor Therapeutics | 160 |
| Taysha Gene Therapies | 73 |
| Savara | 59 |
DBVT News
- 3 days ago - Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of January 31, 2026 - GlobeNewsWire
- 23 days ago - DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing - GlobeNewsWire
- 27 days ago - Information Regarding the Total number of Voting Rights and Total Number of Shares of the Company as of December 31, 2025 - GlobeNewsWire
- 4 weeks ago - Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of December 31, 2025 - GlobeNewsWire
- 7 weeks ago - Peanut Allergy Patch For Kids? DBV Technologies Advances Toward FDA Filing - Benzinga
- 7 weeks ago - DBV Technologies S.A. (DBVT) Discusses Positive Phase III VITESSE Trial Results for Peanut Allergy Patch in Young Children Transcript - Seeking Alpha
- 3 months ago - DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years - GlobeNewsWire
- 3 months ago - DBV Technologies to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference - GlobeNewsWire